TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34774528

Group type: EXPERIMENTAL
Intervention: Bronchial thermoplasty
Number of subjects: 284
Study: 34774574

Group type: EXPERIMENTAL
Intervention: Adherence to BP measurement guidelines
Number of subjects: 2677

Group type: EXPERIMENTAL
Intervention: Counseling on weight, nutrition, and lifestyle
Number of subjects: 2677

Group type: EXPERIMENTAL
Intervention: Follow-up recommendations for high BP
Number of subjects: 2677

Group type: EXPERIMENTAL
Intervention: Scheduled follow-up at appropriate intervals
Number of subjects: 2677

Group type: EXPERIMENTAL
Intervention: Documentation of appropriate diagnosis for third high BP measurement
Number of subjects: 2677

Group type: EXPERIMENTAL
Intervention: Conducting appropriate screening laboratory tests
Number of subjects: 2677

Group type: EXPERIMENTAL
Intervention: Renal ultrasound performance
Number of subjects: 2677

Group type: EXPERIMENTAL
Intervention: Counseling odds related to BMI
Number of subjects: 2677

Group type: EXPERIMENTAL
Intervention: Counseling odds related to BP
Number of subjects: 2677

Group type: EXPERIMENTAL
Intervention: Documentation of hypertension
Number of subjects: 2677
Study: 34774638

Group type: EXPERIMENTAL
Intervention: ERA-2 (after August 2014)
Number of subjects: 4238

Group type: EXPERIMENTAL
Intervention: High-volume centers
Number of subjects: 4238

Group type: EXPERIMENTAL
Intervention: No competition centers
Number of subjects: 4238

Group type: EXPERIMENTAL
Intervention: Male recipients
Number of subjects: 4238

Group type: EXPERIMENTAL
Intervention: Hepatocellular carcinoma
Number of subjects: 4238

Group type: EXPERIMENTAL
Intervention: High-volume center
Number of subjects: 4238

Group type: EXPERIMENTAL
Intervention: MELD ≥30
Number of subjects: 4238
Study: 34774736

Group type: EXPERIMENTAL
Intervention: Family asthma management system scale (FAMSS)
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: FAMSS integration subscale
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: FAMSS family response scores
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: FAMSS collaboration scores
Number of subjects: 388
Study: 34774747

Group type: EXPERIMENTAL
Intervention: Left Atrial Stiffness Index (LA stiffness index)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Left Atrial Reservoir Strain
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Left Atrial Conduit Strain
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Peak Oxygen Uptake (peak VO2)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Quality of Life
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: LA dysfunction
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Therapeutic target
Number of subjects: 75
Study: 34775134

Group type: EXPERIMENTAL
Intervention: Intravenous colistin methanesulfonate (CMS) at 2.5-5.0 mg/kg/day
Number of subjects: 25
Study: 34775220

Group type: EXPERIMENTAL
Intervention: MK-1654 (neutralizing monoclonal antibody)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: MK-1654 (≥ 75 mg)
Number of subjects: 70
Study: 34775477

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 1179

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 1179
Study: 34775592

Group type: EXPERIMENTAL
Intervention: CD57+ NKG2C+ phenotype in SARS-CoV-2 convalescent donors
Number of subjects: 0
Study: 34775804

Group type: EXPERIMENTAL
Intervention: Durvalumab after radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 0
Study: 34775952

Group type: EXPERIMENTAL
Intervention: Accelerometer-based assessment of physical activity (PA)
Number of subjects: 355
Study: 34776249

Group type: EXPERIMENTAL
Intervention: Hospital Anxiety and Depression Scale (HADS) during lockdown
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Hospital Anxiety and Depression Scale (HADS)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Perceived knowledge about COVID-19
Number of subjects: 134
Study: 34776384

Group type: EXPERIMENTAL
Intervention: Geriatric assessment with management (GAM) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 0
Study: 34776902

Group type: EXPERIMENTAL
Intervention: BCI intervention
Number of subjects: 16
Study: 34777207

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34777240

Group type: EXPERIMENTAL
Intervention: Highest quartile of predicted lean body mass index (LBMI) among men
Number of subjects: 9022

Group type: EXPERIMENTAL
Intervention: Highest quartile of predicted fat mass index (FMI) among men
Number of subjects: 9022

Group type: EXPERIMENTAL
Intervention: Highest quartile of predicted lean body mass index (LBMI) among women
Number of subjects: 9022

Group type: EXPERIMENTAL
Intervention: Highest quartile of predicted fat mass index (FMI) among women
Number of subjects: 9022
Study: 34777337

Group type: EXPERIMENTAL
Intervention: Alemtuzumab treatment
Number of subjects: 0
Study: 34777341

Group type: EXPERIMENTAL
Intervention: Low PIV group (PIV < median)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: High PILE score
Number of subjects: 53
Study: 34777343

Group type: EXPERIMENTAL
Intervention: 16 weeks of community-based exercise training (3 x 40 - 60 minute mixed mode aerobic exercises, comprising 10 - 30 minutes aerobic and 30 minutes resistance training)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 16 weeks of community-based exercise training
Number of subjects: 16

Group type: COMPARATOR
Intervention: Acute bout of cycling (45 minutes)
Number of subjects: 16
Study: 34777367

Group type: EXPERIMENTAL
Intervention: hCART19s + Allogeneic Hematopoietic Stem Cell Transplantation (CART+HSCT group)
Number of subjects: 28

Group type: COMPARATOR
Intervention: hCART19s (CART2 group)
Number of subjects: 28

Group type: COMPARATOR
Intervention: hCART19s (CART1 group)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: hCART19s
Number of subjects: 28
Study: 34778037

Group type: EXPERIMENTAL
Intervention: rhTPO (15,000 U, q.d. for 7 days/month for at least 3 months)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Supportive care alone (non-rhTPO)
Number of subjects: 35
Study: 34778141

Group type: EXPERIMENTAL
Intervention: Body composition and physical fitness interventions, specific details not available
Number of subjects: 0
Study: 34778483

Group type: EXPERIMENTAL
Intervention: Bridge-enhanced anterior cruciate ligament repair (BEAR)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Autograft anterior cruciate ligament reconstruction (ACLR)
Number of subjects: 100
Study: 34778571

Group type: EXPERIMENTAL
Intervention: adjunctive dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 34778688

Group type: EXPERIMENTAL
Intervention: App-delivered mindfulness meditation for 6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study: 34778701

Group type: EXPERIMENTAL
Intervention: New medical therapy
Number of subjects: 108
Study: 34778952

Group type: COMPARATOR
Intervention: Immunosuppressive treatment
Number of subjects: 3807

Group type: COMPARATOR
Intervention: Oral alkylating agents with or without steroids
Number of subjects: 3807

Group type: COMPARATOR
Intervention: Calcineurin inhibitors (CNI) with or without steroids
Number of subjects: 3807

Group type: COMPARATOR
Intervention: CNI with or without steroids
Number of subjects: 3807
Study: 34778998

Group type: EXPERIMENTAL
Intervention: Sutimlimab, an investigational C1s inhibitor
Number of subjects: 0
Study: 34779146

Group type: EXPERIMENTAL
Intervention: short-term preoperative endocrine therapy (pET) with tamoxifen or aromatase inhibitors
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: tamoxifen-based pET
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: aromatase inhibitor-based pET
Number of subjects: 622
Study: 34779236

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34779245

Group type: EXPERIMENTAL
Intervention: Mean pulse pressure quartiles (<47, 48-53, 54-59, ≥60 mm Hg)
Number of subjects: 1454

Group type: EXPERIMENTAL
Intervention: Mean pulse pressure as a continuous variable
Number of subjects: 1454

Group type: EXPERIMENTAL
Intervention: Mean arterial pressure in the highest quartile
Number of subjects: 1454

Group type: EXPERIMENTAL
Intervention: Time-dependent area under the receiver operating characteristic curve for hemorrhagic stroke
Number of subjects: 1454
Study: 34779776

Group type: EXPERIMENTAL
Intervention: Ultraprocessed foods (UPFs) consumption
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Parental food educational style (restrictive)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Parental restriction score
Number of subjects: 24
Study: 34779779

Group type: EXPERIMENTAL
Intervention: Automated Text Messaging System (aTS)
Number of subjects: 71
Study: 34779785

Group type: EXPERIMENTAL
Intervention: MyBack website
Number of subjects: 150

Group type: COMPARATOR
Intervention: Wikipedia
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Reliability test
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intraclass correlation coefficient
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Construct validity
Number of subjects: 150
Study: 34779843

Group type: EXPERIMENTAL
Intervention: EyeArt Automated DR Detection System, version 2.1.0
Number of subjects: 893
Study: 34779920

Group type: EXPERIMENTAL
Intervention: Established pelvic LRTIs
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Higher symptom burden and psychological distress
Number of subjects: 107
Study: 34780067

Group type: EXPERIMENTAL
Intervention: SSRIs
Number of subjects: 13029

Group type: COMPARATOR
Intervention: Control
Number of subjects: 13029
Study: 34780106

Group type: EXPERIMENTAL
Intervention: Gene expression analysis for parenchymal injury
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Gene expression analysis for late fibrosis
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Histologic steatohepatitis classifier
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Fibrosis prediction using PC2
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Molecular fibrosis classifier
Number of subjects: 337
Study: 34780125

Group type: EXPERIMENTAL
Intervention: Fine-needle aspiration (FNA) sampling during immunotherapy trials
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Fine-needle aspiration (FNA) sampling
Number of subjects: 44
Study: 34780283

Group type: EXPERIMENTAL
Intervention: Loop Insulin Dosing System
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 34780623

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (1.2 mg/kg every 21 days) and Lenalidomide (20 mg/d for a maximum of 16 cycles)
Number of subjects: 37
Study: 34780683

Group type: EXPERIMENTAL
Intervention: Milvexian 25 mg twice daily
Number of subjects: 1242

Group type: EXPERIMENTAL
Intervention: Milvexian 50 mg twice daily
Number of subjects: 1242

Group type: EXPERIMENTAL
Intervention: Milvexian 100 mg twice daily
Number of subjects: 1242

Group type: EXPERIMENTAL
Intervention: Milvexian 200 mg twice daily
Number of subjects: 1242

Group type: EXPERIMENTAL
Intervention: Milvexian 25 mg once daily
Number of subjects: 1242

Group type: EXPERIMENTAL
Intervention: Milvexian 50 mg once daily
Number of subjects: 1242

Group type: EXPERIMENTAL
Intervention: Milvexian 200 mg once daily
Number of subjects: 1242

Group type: COMPARATOR
Intervention: Enoxaparin 40 mg once daily
Number of subjects: 1242

Group type: EXPERIMENTAL
Intervention: Milvexian (all doses)
Number of subjects: 1242

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 1242
Study: 34780709

Group type: EXPERIMENTAL
Intervention: Ceritinib 510 mg/m²
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Ceritinib 500 mg/m²
Number of subjects: 83
Study: 34780712

Group type: EXPERIMENTAL
Intervention: Li-Fraumeni syndrome
Number of subjects: 480
Study: 34781168

Group type: EXPERIMENTAL
Intervention: LY2780301 500 mg QD + paclitaxel 80 mg/m²
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: LY2780301 + weekly paclitaxel
Number of subjects: 51
Study: 34781256

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine plus amodiaquine (5 monthly rounds)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Control group (untreated children)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Intervention group (Sulfadoxine-pyrimethamine plus amodiaquine)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Community acceptance of SMC
Number of subjects: 350
Study: 34781313

Group type: EXPERIMENTAL
Intervention: Integration of sensor technology in disposable body-worn incontinence materials
Number of subjects: 0
Study: 34781360

Group type: EXPERIMENTAL
Intervention: Early disease (ED) cohort (n = 37)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Advanced disease (AD) cohort (n = 16)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: ED1 cohort (n = 24)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: ED2 cohort (n = 13)
Number of subjects: 59

Group type: COMPARATOR
Intervention: AD cohort (n = 16)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: ED cohort (n = 37)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Unrelated umbilical cord grafts
Number of subjects: 59
Study: 34781890

Group type: EXPERIMENTAL
Intervention: Clinical measured ultrafiltration
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Real ultrafiltration
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Storage conditions and type of dialysate package
Number of subjects: 261

Group type: COMPARATOR
Intervention: Non-PVC package
Number of subjects: 261
Study: 34781913

Group type: EXPERIMENTAL
Intervention: RVO affected eyes
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: RVO contralateral eyes
Number of subjects: 79

Group type: COMPARATOR
Intervention: Healthy control eyes
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: PDR eyes
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: NPDR eyes
Number of subjects: 79

Group type: COMPARATOR
Intervention: NDR eyes
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Retinal blood flow in RVO eyes
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Retinal blood flow in contralateral eyes
Number of subjects: 79

Group type: COMPARATOR
Intervention: Retinal blood flow among the four groups
Number of subjects: 79
Study: 34781989

Group type: EXPERIMENTAL
Intervention: Low-dose naltrexone (LDN)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 34781991

Group type: EXPERIMENTAL
Intervention: 48-Fr diameter calibration bougie
Number of subjects: 0

Group type: COMPARATOR
Intervention: 34 to 38-Fr diameter calibration bougie (standard care)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (48-Fr and 34 to 38-Fr)
Number of subjects: 0
Study: 34782015

Group type: EXPERIMENTAL
Intervention: Individualized nutritional intervention (dietary counseling and a nutrition plan before discharge, combined with two home visits over 4 weeks)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Individualized nutritional intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard treatment (control)
Number of subjects: 40
Study: 34782339

Group type: EXPERIMENTAL
Intervention: Active chronic conditions and geriatric syndromes
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Polypharmacy (geriatric syndrome)
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Multimorbidity clusters identified
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Patient-level variables
Number of subjects: 740
Study: 34782341

Group type: EXPERIMENTAL
Intervention: Robot-assisted nipple-sparing mastectomy (RNSM)
Number of subjects: 12
Study: 34782428

Group type: EXPERIMENTAL
Intervention: Toripalimab plus intensity-modulated radiotherapy (IMRT)
Number of subjects: 25
Study: 34782683

Group type: EXPERIMENTAL
Intervention: Packed red blood cell transfusion (mean 2.93 ± 3.05 units)
Number of subjects: 282

Group type: COMPARATOR
Intervention: No blood transfusion (control group)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Packed red blood cell transfusion
Number of subjects: 282
Study: 34783663

Group type: EXPERIMENTAL
Intervention: Smartband and smartphone intervention with mindfulness exercises
Number of subjects: 100
Study: 34783675

Group type: EXPERIMENTAL
Intervention: mHealth app called PurUmeed Aaghaz
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard face-to-face counseling
Number of subjects: 300
Study: 34783716

Group type: EXPERIMENTAL
Intervention: Systemic agents for VHL-related ccRCC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Expert-opinion-based protocols
Number of subjects: 0
Study: 34783978

Group type: EXPERIMENTAL
Intervention: Overlap syndrome (OVS) patients
Number of subjects: 252
Study: 34784056

Group type: EXPERIMENTAL
Intervention: Nivolumab plus Ipilimumab (NIVO + IPI)
Number of subjects: 28
Study: 34784242

Group type: EXPERIMENTAL
Intervention: Heart Failure patients
Number of subjects: 18

Group type: COMPARATOR
Intervention: Hemodialysis patients
Number of subjects: 18
Study: 34784301

Group type: EXPERIMENTAL
Intervention: Dialysis treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: CKD without dialysis
Number of subjects: 0
Study: 34784359

Group type: EXPERIMENTAL
Intervention: Endovascular baroreflex amplification (EVBA)
Number of subjects: 14
Study: 34784492

Group type: EXPERIMENTAL
Intervention: Elexacaftor/Tezacaftor/Ivacaftor
Number of subjects: 0
Study: 34784496

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 34784657

Group type: EXPERIMENTAL
Intervention: Patients with atrial fibrillation (AF)
Number of subjects: 894

Group type: EXPERIMENTAL
Intervention: Patients with lower BMI
Number of subjects: 894

Group type: EXPERIMENTAL
Intervention: Patients with worse renal function
Number of subjects: 894
Study: 34784815

Group type: EXPERIMENTAL
Intervention: ADHD
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: MCI
Number of subjects: 106

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 106
Study: 34784941

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.7μg/kg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Propofol (0.5 mg/kg)
Number of subjects: 120
Study: 34784953

Group type: EXPERIMENTAL
Intervention: Practice facilitation intervention (including quality improvement coaching, EHR support, training, and expert consultation)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Telehealth services plus ongoing practice facilitation
Number of subjects: 35

Group type: COMPARATOR
Intervention: Continued practice facilitation alone
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy for AUD or referral for AUD services
Number of subjects: 35
Study: 34785305

Group type: EXPERIMENTAL
Intervention: Guiding Good Choices (GGC) parenting intervention
Number of subjects: 3750

Group type: COMPARATOR
Intervention: Usual pediatric primary care practice
Number of subjects: 3750
Study: 34785541

Group type: EXPERIMENTAL
Intervention: TechCare App intervention (6-week duration, personalized guided self-help based on CBT principles)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: TechCare App intervention
Number of subjects: 16
Study: 34785540

Group type: EXPERIMENTAL
Intervention: Alopecia areata (AA) patients
Number of subjects: 5200000
Study: 34785545

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 34785663

Group type: EXPERIMENTAL
Intervention: Replication-competent SARS-CoV-2 in extrapulmonary organs
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 genome diversity and mutations
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Viral loads in lungs and plasma
Number of subjects: 13
Study: 34785698

Group type: EXPERIMENTAL
Intervention: WT2725 dosing emulsion
Number of subjects: 0
Study: 34786087

Group type: EXPERIMENTAL
Intervention: OCT-guided drug coated balloon (DCB)
Number of subjects: 54
Study: 34786477

Group type: EXPERIMENTAL
Intervention: Nilotinib, 300 mg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Nilotinib, 150 mg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 34786649

Group type: EXPERIMENTAL
Intervention: L-Ornithine phenylacetate
Number of subjects: 0
Study: 34786667

Group type: EXPERIMENTAL
Intervention: Peptide p5+14 radiolabeled with iodine-124, single intravenous infusion
Number of subjects: 3
Study: 34786746

Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange (TPE) using centrifugation technique
Number of subjects: 185

Group type: COMPARATOR
Intervention: 4% albumin
Number of subjects: 185

Group type: COMPARATOR
Intervention: Fresh frozen plasma (FFP)
Number of subjects: 185
Study: 34786868

Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Alteplase (original mismatch cohort)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo (original mismatch cohort)
Number of subjects: 225
Study: 34787462

Group type: EXPERIMENTAL
Intervention: Microbial profiles of NSCLC patients
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Combined machine learning model using both microbiota
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Sputum microbiota
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Pseudomonas aeruginosa abundance in brain metastasis
Number of subjects: 121
Study: 34787590

Group type: EXPERIMENTAL
Intervention: Automated treatment (AT)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard treatment (ST)
Number of subjects: 500
Study: 34787803

Group type: EXPERIMENTAL
Intervention: BREST score
Number of subjects: 1386

Group type: EXPERIMENTAL
Intervention: PREDICA score
Number of subjects: 1386
Study: 34788228

Group type: EXPERIMENTAL
Intervention: Cosyntropin infusion (ACTH(1-24))
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Cosyntropin infusion
Number of subjects: 17
Study: 34788338

Group type: EXPERIMENTAL
Intervention: Smart Triage program (digital triage platform for pediatric sepsis)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis of Smart Triage program
Number of subjects: 0
Study: 34788401

Group type: EXPERIMENTAL
Intervention: Venetoclax plus dose-adjusted R-EPOCH (VR-EPOCH)
Number of subjects: 26
Study: 34788416

Group type: EXPERIMENTAL
Intervention: Leadless VVI
Number of subjects: 6219

Group type: COMPARATOR
Intervention: Transvenous VVI
Number of subjects: 6219